A Phase 3 interventional study of 'TS-172 20~60 mg/day in Hyperphosphatemia Patients on Peritoneal Dialysis, sponsored by Taisho Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.
Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 34th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 in phase 3, and was the 40th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 117 across the 36 interventional studies, 762 across the 4 observational. Of the 36 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 41 have an industry lead sponsor. The 9 most frequent:
Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.
Taisho Pharmaceutical Co., Ltd. has 7 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hyperphosphatemia with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548840Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2026-11-30 |
| NCT07285291Phase 3Taisho Pharmaceutical Co., Ltd.A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | 2026-12-22 |
| NCT07548853Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis | 2027-05-31 |
| NCT07285304Phase 3Taisho Pharmaceutical Co., Ltd.A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Hyperphosphatemia with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 'TS-172 20~60 mg/day
oral administration of TS-172 20\~60 mg/day
Achievement rate of the target serum phosphorus level
Time frame: Week 8
Change from baseline in serum concentration of phosphorus
Time frame: Up to Week 16
Concentration of corrected serum calcium
Time frame: Up to Week 16
Serum Ca × P product
Time frame: Up to Week 16
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taisho Pharmaceutical Co., Ltd. →